Planchard et al. investigated whether p38 MAPK activity contributed to excision repair cross-complementation group 1 (ERCC1) mRNA expression and viability of cisplatin in lung cancer cell lines from light or never smokers. The gene discussed is ERCC1; the disease is lung carcinoma.